Aripiprazole for the treatment of pediatric bipolar I disorder: A 30-week, randomized, placebo-controlled study

Robert L. Findling, Christoph U. Correll, Margaretta Nyilas, Robert A. Forbes, Robert D. Mcquade, Na Jin, Svetlana Ivanova, Raymond Mankoski, William H. Carson, Gabrielle A. Carlson

Research output: Contribution to journalArticlepeer-review


Objective: To evaluate the long-term efficacy, safety, and tolerability of aripiprazole in pediatric subjects with bipolar I disorder. Methods: A randomized, double-blind, 30-week, placebo-controlled study of aripiprazole (10 or 30mg/day) in youths (10-17years) with bipolar I disorder (manic or mixed) ± psychotic features (n=296) was performed. After four weeks, acute treatment completers continued receiving ≤26weeks of double-blind treatment (n=210). The primary outcome was Young Mania Rating Scale (YMRS) total score change. Results: Of the 210 subjects who entered the 26-week extension phase, 32.4% completed the study (45.3% for aripiprazole 10mg/day, 31.0% for aripiprazole 30mg/day, and 18.8% for placebo). Both aripiprazole doses demonstrated significantly (p<0.001) greater improvements in YMRS total score at endpoint compared with placebo in protocol-specified last observation carried forward analyses, but not in observed case or mixed-model repeated measures at week 30. Overall time to all-cause discontinuation was longer for aripiprazole 10mg/day (15.6weeks) and aripiprazole 30mg/day (9.5weeks) compared with placebo (5.3weeks; both p<0.05 versus placebo). Both aripiprazole doses were significantly superior to placebo regarding response rates, Children's Global Assessment of Functioning and Clinical Global Impressions-Bipolar severity of overall and mania scores at endpoint in all analyses. Commonly reported adverse events included headache, somnolence, and extrapyramidal disorder. Conclusions: Aripiprazole 10mg/day and 30mg/day were superior to placebo and generally well tolerated in pediatric subjects with bipolar I disorder up to 30weeks. Despite the benefits of treatment, completion rates were low in all treatment arms.

Original languageEnglish (US)
Pages (from-to)138-149
Number of pages12
JournalBipolar Disorders
Issue number2
StatePublished - Mar 2013


  • Aripiprazole
  • Bipolar disorder
  • Pediatric
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Aripiprazole for the treatment of pediatric bipolar I disorder: A 30-week, randomized, placebo-controlled study'. Together they form a unique fingerprint.

Cite this